Drug shortages adding to workloads at Irish pharmacies
Irish Pharmacy Union
(IPU).
The IPU said the medicine shortages, largely driven by demand for treatments such as hormone replacement therapy, GLP-1 agonists for weight loss such as
Ozempic
and treatments for
ADHD
, are increasingly negatively affecting patient outcomes.
According to the IPU survey, pharmacists and their teams are now spending more than six hours each week managing shortages, up from between five and 10 hours a month in 2018.
The majority of respondents (95 per cent) reported contacting prescribers regularly to source alternatives with 83 per cent saying they are borrowing stock from other pharmacies, described by the IPU as 'labour-intensive efforts that often go unrecognised and unremunerated'.
READ MORE
The survey of more than 300 community pharmacists showed a persistent high rate of medicine shortages, with 57 per cent of respondents encountering 40 or more shortages in the past four months.
The poll carried out in March and April saw 57 per cent also say shortages had 'significantly increased,' and while this was down from 82 per cent in 2024, most respondents (78 per cent) expect the problem to worsen over the coming year.
Some 71 per cent reported negative patient outcomes due to the shortages, up from 66 per cent last year, with a further 82 per cent believing pharmacists should have greater clinical discretion in sourcing generic alternatives.
[
Plan to make pharmacies display dispensing fees will not make 'a blind bit of difference'
Opens in new window
]
While medicine shortages are largely 'multifactorial,' current shortages are largely driven by demand, according to Clare Fitzell, the IPU's secretary general.
'When a medicine is in short supply, this can interrupt treatment, something which can be a cause of distress for patients and their families.
'Whilst medicine shortages may be a feature of modern health systems, we need to ensure that the impact of such shortages is minimised to the greatest extent possible,' she said.
Ms Fitzell said the survey findings highlight a profession under pressure, saying: 'This is unsustainable and requires urgent, system-wide solutions.'
The IPU is calling on the
Department of Health
to expedite the Health Miscellaneous Provisions Bill 2024, which will facilitate the substitution of medicines by pharmacists in the case of shortages without needing to revert to the prescriber.
The medicine substitution protocols, which will speed up the process, will also benefit patients and prescribers, Ms Fitzell said.
While describing as 'significant' a commitment made in the programme for government to support pharmacists to adopt a proactive approach to manage shortages, Ms Fitzell said: 'This now needs to be progressed at pace.'
The issue is due to be discussed at the Irish Pharmacy Union conference on Saturday, which Minister for Health
Jennifer Carroll MacNeill
is expected to attend.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Irish Times
3 hours ago
- Irish Times
Biological treatment service for rabies ceases, leading to fears for people exposed to virus
People exposed to rabies are at risk of being 'missed, lost to follow up or inappropriately managed' after a service providing biological treatment for such patients stopped operating, a senior HSE official has said. Until the start of this month, a service operated out of Cherry Orchard Hospital, Dublin, was responsible for the assessment of patients and delivery of 'critical' biologics to patients with acute post-exposure treatment of rabies, diphtheria and botulinum. On July 3rd, Colm Henry , chief clinical officer at the HSE, wrote to the country's regional executive officers and regional clinical directors following the retirement of the doctor who ran the Cherry Orchard service. Following his retirement on July 4th, the service would cease to operate, Dr Henry said. READ MORE 'While this service had never been commissioned as a national service, it had, in effect, provided advice and treatment on management of potentially or actually exposed patients for many years from all over the country,' his letter said. Dr Henry said in light of the 'importance' of this service, the National Health Protection Office has been working with key partners and stakeholders to support implementation of a new regional service model. 'There are risks, while these discussions are taking place, of gaps in service and therefore potential for a person with a rabies prone exposure being missed, lost to follow up or inappropriately managed,' his letter said. Dr Henry requested the regional executive officers to work with stakeholders and structures to 'ensure provision of service and further development of same to address issues and risks identified'. According to his letter, there are areas in which there has been consensus in relation to the establishment of regional services, including a proposed role for emergency departments, which will see and assess new presentations. However, he also highlighted a number of 'issues requiring further consideration/agreement' such as the provision of out-of-hours services or infectious diseases on-call hours for weekends and bank holidays. In a statement, a spokesman for the HSE said the service for rabies exposure was 'formally reorganised on a regional footprint to better meet the needs of local populations'. The spokesman said a working group will work with implementation committees to 'mitigate any risk relating to access to assessment and care for patients, potentially created by the standing down of a previously available service, which had been in place for many years'. Rabies is a rare viral infection, but a person's risk of contracting it becomes significant if they travel to parts of the world where rabies is common in land-based animals. If a person is exposed to an animal in such countries, they must immediately seek medical advice and report this contact to a local hospital or clinic to enable assessment. Diphtheria is an acute bacterial disease, mainly affecting the respiratory system. The most recent case of diphtheria in Ireland was in 2016. Botulism is a rare but life-threatening condition caused by toxins produced by Clostridium botulinum bacteria. There has been a surge in botulism poisonings in England over the past six weeks.
The Journal
8 hours ago
- The Journal
Weight loss injections become more attainable as they enter beauty clinics
THE MOVE TO bring obesity treatment injections further into mainstream use has taken another step forward with the news that it's now being offered outside strictly medical settings. Thérapie Clinics, best known for lip fillers and laser hair removal treatments, has now launched the doctor-led service Thérapie Health to provide access to Wegovy obesity treatment injections in Ireland. The company says it is a 'medically managed programme for those who meet the correct criteria'. The move has been largely appreciated by experts and patients who are advocating for increased accessibility to the medication to prevent people looking towards the black market. According to the HSE, Ireland has one of the highest levels of obesity in Europe , with 60% of adults living with the disease. Obesity treatment injections are intended to fight obesity and its associated diseases, such as type 2 diabetes, cardiovascular disease, respiratory disease, several types of cancer, pain and musculoskeletal disorders. It costs €365 to begin using obesity treatment injections at Thérapie Health, including €220 per month for the Wegovy medication. Each follow-up appointment costs €35. Belinda Hogan, who lost over 80 pounds using Ozempic between 2022 and 2023, told The Journal she welcomes an increase in the availability of the obesity treatment injections. 'I would say it's a good thing because if you get to go in and sit in front of a doctor, they can check your health markers,' she said. She highlighted the importance of doctors being knowledgeable about the medications and clearly communicating the administration process to patients. Advertisement Hogan runs an online coaching programme for users of weight loss injections, she said she receives messages every day from people who have been prescribed the medication but don't know how to use it. She also said cost can be a barrier to accessing obesity treatment injections. 'It's wealthcare as opposed to healthcare. It's not fair,' she said. 'It doesn't just help you lose weight, it staves off other health medications. It stopped me getting diabetes, and being an absolute drain on the system,' she added. Hogan uses an online doctor service based in Northern Ireland to access her prescription to Mounjaro, as the medication is cheaper in the North. Mounjaro medication generally ranges from €285 to €475 per month in pharmacies in the Republic of Ireland, in comparison to £133.40 (€153.94) to £254.91 (€294.06) per month in pharmacies in Northern Ireland. Aisling O'Leary lost over 100 pounds using Ozempic between 2022 and 2023. She said: 'I'm a huge advocate for these medications to be used for treatment of chronic obesity, but it is a disease, and it should be done right through the correct channels.' 'People need to be making monthly check-ups, but also need to be referred to a dietician and counsellor to treat all parts of the obesity disease, not just take the medication and hope for the best,' she added. O'Leary, who is a medical card holder, paid €139.50 monthly for Ozempic during her weight loss journey, which took a considerable chunk out of her income as a pensioner. She said the medication should be available on the drug payment scheme, adding that many people travel to Northern Ireland to access Mounjaro. Dr Francis Finucane, Consultant Endocrinologist with the National Clinical Programme for Obesity, told The Journal he welcomes the move by Thérapie. Read Next Related Reads Will Ireland follow the UK with free Mounjaro jabs? Minister says assessment to be ready by next year He said: 'It appears to be a bona fide clinically supervised doctor service with carefully considered criteria'. Dr Finucane said the cost of the drugs act as a barrier for people who could benefit from their use and criticised the lack of funding for obesity treatment medication in Ireland. Weight loss injections in Ireland currently cost between €120 and €475 per month. He said: 'They are extremely expensive considering they are being used for legitimate a disease.' 'The Health Service will not fund effective proven treatment of disease', he said, adding that services relating to diseases from alcohol and smoking are funded 'generously and compassionately' by the state. Minister for Health Carroll MacNeill said that Wegovy will be available as early as the end of 2025 as part of the HSE's reimbursement schemes, including the Medical Card Scheme and Drugs Payment Scheme. Another weight loss injection, Saxenda, has been available on the scheme since January 2023. Dr Finucane warned that caution must be exercised when accessing obesity treatment injections. 'There are unscrupulous actors out there using these drugs for cosmetics, gaining financially from vulnerable people who want to be skinny,' he said. He said that in some cases obesity treatment injections are not being used for their intention of fighting obesity and the connected health issues, but rather as a cosmetic enhancement to fulfil the 'cultural desire for thinness'. According to Dr Finucane, the aesthetical desire to be thin 'mopped up the demand for the medication', in part contributing to the shortage of these medications in 2023. Readers like you are keeping these stories free for everyone... A mix of advertising and supporting contributions helps keep paywalls away from valuable information like this article. Over 5,000 readers like you have already stepped up and support us with a monthly payment or a once-off donation. Learn More Support The Journal
Irish Times
14 hours ago
- Irish Times
HSE apologises over delay in acting on X-ray showing man aged 91 had swallowed dentures
The HSE has apologised to the family of a 91-year-old man who died with choking complications after a hospital took a week to act on an X-ray that revealed he had swallowed dentures. At the High Court sitting in Cork, Ms Justice Carmel Stewart approved a €55,000 award on Wednesday to the family of Daniel O'Leary, late of Knockbrack in Banteer, Co Cork. The court heard how on July 26th, 2022, Mr O'Leary, a resident at Kanturk Community Hospital, Co Cork, started coughing while sitting in a chair. He was uncomfortable and complained about something stuck in his throat. READ MORE He was holding his hands to his throat and his partial bottom denture of two teeth was missing. Staff went to his aid and he was transferred to University Hospital Limerick. Paramedics told doctors he had possibly inhaled a denture consisting of two lower teeth. He was examined in the emergency department, and X-rays showed no evidence of the dentures or any foreign body. Mr O'Leary was admitted to hospital. He was further assessed the following day and again a doctor found no evidence that his upper airway was obstructed. A diagnosis of respiratory sepsis was made on a background of likely aspiration due to impaired swallow. Mr O'Leary was given fluids and antibiotics intravenously. He also received oxygen therapy. He was assessed two days later when he appeared to be improving. He remained in hospital over the bank holiday weekend, with his care being taken over by a consultant physician and geriatrician on August 2nd. Ms Justice Stewart was told a chest X-ray carried out on his arrival at the hospital on July 26th was only reported on July 30th. It showed 'densities in the upper neck, likely reflecting a foreign body'. The court was told there was no evidence the X-ray report had been seen or acted on by medics in the hospital until the consultant geriatrician came on duty on August 2nd. A CT scan carried out on August 3rd did not detect any foreign body in Mr O'Leary's neck or chest. However, later that day nursing staff carried out a suctioning procedure on the patient and detected dentures in the lowest part of his throat. The ENT team removed the dentures on August 4th, 2022, nine days after he was taken to hospital. Mr O'Leary continued to deteriorate physically and his care became palliative. He was brought back to Kanturk Community Hospital where he died peacefully on August 12th, 2022. Eamon Shanahan, for his family, said they received an apology from the HSE. In the apology the health service acknowledged the delay in the review of the relevant X-ray and said it has 'learned from the incident' and implemented a recommendation identified by the coroner at the inquest concerning Mr O'Leary's death. 'We wish to apologise for the failings in the care provided and for the distress and upset that this has caused,' it said. In effect there was a week between the X-ray, which showed a potential blockage, and when it was acted upon. Ms Justice Stewart extended her condolences to Mr O'Leary's family. 'Your father had a long and fruitful life,' she said. 'There is never a good time to lose a loved one, or to endure the trauma he endured. It doesn't bear thinking about. Hopefully you can put this behind you and reflect on the good times.'
